Valo SPAC Presentation Deck

Biological discovery: Opal's human-based capabilities designed to enable discovery of targets linked to precisely selected patient populations PATIENT SUBGROUP MOLECULE MECHANISM BIOMARKER OUTCOME Valo Designed to causally link therapeutic intervention to target & pathway mechanism to physiological biomarkers of patient fit & response to disease-relevant outcomes (e.g., motor symptoms) within biologically real patient subgroups across multiple real-world, clinical, and preclinical data sources ILLUSTRATIVE NEURODEGENERATIVE EXAMPLE 18 34 32 85 Clinical embedding subgroup 18 32 85 Clinical severity & progression ++ + Presentation / medication diuretics constipation muscle relaxant 0.05 MAOi restless leg stiffness 0.00 0.04 MAOI, COMTI, amantadine, etc 0.02 seizure/psych 0.00 0.050 0.025 0.000 Subgroup demographics 40% female (46%) 142/7121 subjects 50 age 37% female (46%) 237/7121 subjects 50 age 100 50 34% female (46%) 362/7121 subjects age 100 BIOLOGICAL DISCOVERY 100 Biosignature Bio- signature-1 Bio- signature-2 2Q21 18

View entire presentation